The company became the 17th drug manufacture to enter a Most Favored Nation prescription pricing agreement.
Regeneron Pharmaceuticals on April 23 became the latest drug manufacturer to enter a Most Favored Nation drug pricing agreement with the United States.
President Donald Trump announced the deal from the Oval Office.
“With this announcement, 17 of the world’s largest pharmaceutical companies, representing 80 percent of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world,” Trump said.
With Regeneron’s agreement, all of the pharmaceutical CEOs that Trump directly asked to join the Most Favored Nation pricing model have responded favorably.
Trump has said his aim in making the deals is to correct the long-standing practice by pharmaceutical companies of charging Americans about three times more for prescription medications than those in other countries.
Regeneron CEO Leonard Schleifer touted the deal as a benefit to both the country and scientific innovation.
“We’ve been arguing for more than a decade that other wealthy nations have been getting a free ride on American innovation,” Schleifer said. “Discovering cures is perhaps the hardest scientific challenge humans undertake.”
The company announced a new gene therapy called Otarmeni earlier in the day, which has been proven to reverse genetic hearing loss in children. Regeneron pledged to provide it in the United States for free.
Regeneron Chief Scientific Officer Dr. George Yancopoulos said, “We do this to highlight the power of disruptive biotech innovation and all the good that we can bring to all of our lives and our health.”
Also, cardiovascular medication Praluent will be available for direct patient purchase through TrumpRx.gov.
In keeping with the Most Favored Nation policy, Regeneron will also lower Medicaid prices and offer future medications in the United States to align with those in other countries.
Regeneron will continue investing in domestic research and manufacturing.
Terms of the Agreements
The president announced the most favored nation prescription drug policy in May 2025, saying in a social media post, “The United States will pay the same price as the Nation that pays the lowest price anywhere in the World.”
The confidential nature of the agreements makes their impact difficult to assess.
Trump said his vision was for drugmakers to offer their best price to Medicaid on their “full portfolio of existing drugs” and to do the same for all new drugs offered in Medicaid, Medicare, and through commercial insurers.
